32 minutes ago | News
Efforts by India and the European Union to strengthen trade are threatening India's ability to deliver life-saving medicines to the world's poorest, analysts say as the two sides resume protracted negotiations on a free-trade pact.
|
39 minutes ago | News
Study results published in the journal Science Translational Medicine suggests that an experimental gene therapy improved vision in the second eye of the previously treated individuals, Bloomberg reported Wednesday.
|
43 minutes ago | News
An FDA panel on Wednesday voted 12-1 that the benefits of Amgen’s Xgeva (denosumab) did not outweigh its risks in patients with castrate-resistant prostate cancer (CRPC).
|
49 minutes ago | News
The FDA warned that proton-pump inhibitors (PPIs) can trigger the development of Clostridium difficile-associated diarrhea (CDAD).
|
53 minutes ago | News
Watson Pharmaceuticals CEO Paul Bisaro said the company has around $6 billion to spend on acquisitions as it looks to buy brand-name drug assets, signaling a move away from the company's focus on generic medicines, Bloomberg reported Thursday.
|
1 hour ago | Video
CNN’s The Situation Room discusses the current dispute over health care coverage for contraception. Will there be a contraception compromise?
|
22 hours ago | News
Watson Pharmaceuticals Inc. said Wednesday it settled a patent lawsuit brought by a unit of Johnson & Johnson over a generic version of the birth control drug Ortho Tri-Cyclen Lo.
|
Feb 8 | News
SAN DIEGO (AP) — Diagnostics company Illumina Inc. again rejected a $5.7 billion offer from Roche AG on Tuesday, saying the Swiss drugmaker's bid was "grossly inadequate."
|
Feb 8 | News
CAMBRIDGE, Mass. (AP) — Move over, coffee and Red Bull. A Harvard professor thinks the next big thing will be people inhaling their caffeine from a lipstick-sized tube. Critics say the novel product is not without its risks.
|
Feb 8 | News
Amgen will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases (spread of cancer to the bone) at today's meeting of the U.S. FDA Oncologic Drugs Advisory Committee (ODAC).
|